Especially in estrogen receptor positive (ER+) BC, validated Ki-67 cut-offs, alone or in combination with gene expression assays, are commonly used to guide treatment strategies,1 such as the use of adjuvant chemotherapy or the use of Cyclin-Dependent Kinase 4/6 (CDK4/6) inhibitors.12 This evidence concerns the gene ESR1 and breast cancer.